Harrell LE, Parsons DS, Conger K, Kolasa K (2002) ß1 adrenergic antagonist effect on brain muscarinic cholinergic receptors. Neuroscience 2002 Abstracts 685.13. Society for Neuroscience, Orlando, FL.
Summary: Degeneration of basal forebrain cholinergic system and sympathetic ingrowth appear to be pathologic changes in Alzheimer’s Disease (AD). An imbalance between these systems may mediate cognitive deficit in AD. To model this situation, 192-IgG-Saporin, a specific cholinergic immunotoxin, was infused intraventricularly to induce cholinergic denervation and sympathetic ingrowth into cortex and hippocampus. After 8 weeks of intraperitoneal injection of Metoprolol, β1 antagonist, at 2.5 mg/kg and 5 mg/kg, the Kd and Bmax of dorsal hippocampus (DH), anterior (AC) and entorhinal (EC) cortex was determined via [3H]-QNB, muscarinic antagonist, binding. Low dose Metoprolol increased Kd in the sympathetic ingrowth, cholinergic denervation, ganglionectomized groups compared to control and vehicle groups (p<.05). Affinity of AC=DH but was > than EC (p<.02). Bmax was greater in AC than DH (p<.05) > than EC (p<.02). Controls and ganglionectomized had > Bmax in AC and EC (p<.03). EC had > Bmax in control and ganglionectomized animals (p<.04). High dose Metoprolol induced a greater affinity in DH>AC>EC (p<.05). No effect was found on Bmax.The results of our study suggest that a β1 antagonist, which is used clinically, can alter the number and affinity of cholinergic receptors, which in turn could potentially alter the AD patients' response to cholinergic therapy.
Related Products: 192-IgG-SAP (Cat. #IT-01)